We are contrasting Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) and Kala Pharmaceuticals Inc. (NASDAQ:KALA) on their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals Inc.	184.35M	7.20	13.01M	0.24	119.96
Kala Pharmaceuticals Inc.	N/A	0.00	52.81M	-3.30	0.00

Table 1 highlights Vanda Pharmaceuticals Inc. and Kala Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the return on assets, return on equity and net margins of Vanda Pharmaceuticals Inc. and Kala Pharmaceuticals Inc.

	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals Inc.	7.06%	5.9%	4.6%
Kala Pharmaceuticals Inc.	0.00%	-72.1%	-52.7%

Liquidity

Vanda Pharmaceuticals Inc. has a Current Ratio of 6 and a Quick Ratio of 6. Competitively, Kala Pharmaceuticals Inc.’s Current Ratio is 6.3 and has 6.3 Quick Ratio. Kala Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Vanda Pharmaceuticals Inc.

Analyst Recommendations

Vanda Pharmaceuticals Inc. and Kala Pharmaceuticals Inc. Ratings and Recommendations are available on the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Vanda Pharmaceuticals Inc.	0	1	5	2.83
Kala Pharmaceuticals Inc.	0	0	0	0.00

Vanda Pharmaceuticals Inc. has a consensus target price of $40.17, and a 58.77% upside potential.

Insider and Institutional Ownership

The shares of both Vanda Pharmaceuticals Inc. and Kala Pharmaceuticals Inc. are owned by institutional investors at 99.85% and 52.1% respectively. 0.2% are Vanda Pharmaceuticals Inc.’s share held by insiders. Insiders Competitively, held 3.2% of Kala Pharmaceuticals Inc. shares.

Performance

In this table we provide the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Vanda Pharmaceuticals Inc.	14.5%	40.2%	57.1%	58.4%	106.26%	88.62%
Kala Pharmaceuticals Inc.	-8.57%	-24.31%	-48.89%	-56.95%	-69.72%	-68.85%

For the past year Vanda Pharmaceuticals Inc. has 88.62% stronger performance while Kala Pharmaceuticals Inc. has -68.85% weaker performance.

Summary

Vanda Pharmaceuticals Inc. beats Kala Pharmaceuticals Inc. on 10 of the 11 factors.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The companyÂ’s marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The company markets its products in the United States, Canada, Europe Union, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The companyÂ’s product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease. It also develops KPI-285, a receptor kinase inhibitor, which is in preclinical studies for the treatment of various retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.